Tenax details LEVEL-2 protocol changes and Type C meeting after LEVEL miss
Tenax Therapeutics reported third-quarter 2026 results and outlined a predictive enrichment strategy for its LEVEL-2 trial following completed statistical analysis of the failed LEVEL study.
SEC filing